
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Diginex Ltd

(Name of Issuer)

Ordinary Shares, par value US\$0.0004

(Title of Class of Securities)

(CUSIP Number)

**James A. Prestiano
c/o Loeb & Loeb, 345 Park Avenue
New York, NY, 10154
212-407-4000**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/17/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Rhino Ventures Limited

2 Check the appropriate box if a member of a Group (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

Sole Voting Power

33,048,073.00

Shared Voting Power

0.00

Sole Dispositive Power

33,048,073.00

Shared Dispositive Power

0.00

Aggregate amount beneficially owned by each reporting person

33,048,073.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)

40.1 %

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: * Percentage for Rhino Ventures Limited is based on 82,446,496 ordinary shares outstanding as of August 10, 2026, including the 32,316,366 ordinary shares underlying the warrants held by Ventures Limited, which are exercisable within the next 60 days.

SCHEDULE 13D

CUSIP No.

Name of reporting person

Miles Pelham

Check the appropriate box if a member of a Group (See Instructions)

SEC use only

Source of funds (See Instructions)

PF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6	Citizenship or place of organization
	UNITED KINGDOM
	Sole Voting Power
7	
Number of Shares Beneficially Owned by Each Reporting Person	33,351,473.00
	Shared Voting Power
8	0.00
	Sole Dispositive Power
9	33,351,473.00
With:	Shared Dispositive Power
10	0.00
11	Aggregate amount beneficially owned by each reporting person
	33,351,473.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	40.5 %
14	Type of Reporting Person (See Instructions)
	IN
Comment for Type of Reporting Person:	** Percentage for Miles Pelham is based on 82,446,496 ordinary shares outstanding as of August 10, 2026, including the 32,316,366 ordinary shares underlying the warrants held by Ventures Limited, which are exercisable within the next 60 days.

SCHEDULE 13D

Item 1.	Security and Issuer
	Title of Class of Securities:
(a)	Ordinary Shares, par value US\$0.0004
	Name of Issuer:
(b)	Diginex Ltd
	Address of Issuer's Principal Executive Offices:
(c)	25 Wilton Road, Victoria, London, Greater London, SW1V 1LW, UNITED KINGDOM , 00000000.
Item 1 Comment:	This Amendment No. 6 relates to the Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on behalf of Rhino Ventures Limited, a Cayman Islands company ("Rhino Cayman") and Miles Pelham ("Mr. Pelham"), Rhino Cayman are wholly owned and managed by Mr. Pelham and Mr. Pelham has voting and dispositive control over the securities held by Rhino Cayman (the "Schedule 13D"), relating to the ordinary shares, \$0.0004 par value per share (the "Ordinary Shares") of Diginex Limited, a Cayman Islands exempted company ("Diginex" or the "Issuer"), filed with the Commission on January 30, 2025, as amended on March 27, 2025, as amended on August 29, 2025, as amended on October 27, 2025, and as amended on March 20, 2026 (the "Schedule 13D"). The information set forth in the Schedule 13D is amended by this Amendment No. 6 only as specifically stated. Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to them in the Schedule 13D. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. As of August 10, 2026, the Issuer had 50,130,130 Ordinary Shares issued and outstanding. On April 28, 2026, the issuer effected a one-for-eight share consolidation of the Ordinary Shares (the "Share Consolidation"). The number of Ordinary Shares reported on this Schedule 13D have been adjusted to reflect the Share Consolidation.
Item 2.	Identity and Background
(a)	This Schedule 13D is filed by Rhino Cayman, a Cayman Islands company and Mr. Pelham. Rhino Cayman is wholly-owned and managed by Mr. Pelham, who has voting and dispositive control over the Ordinary Shares held by Rhino

Cayman. Mr. Pelham is a British citizen. Rhino Cayman and Mr. Pelham and referred to herein collectively as the "Reporting Persons."

- (b) The principal business and principal office address for Rhino Cayman is 90 Fort Street, Suite 303, Grand Cayman, Cayman Islands. The principal business and principal office address for Mr. Pelham is 90 Fort Street, Suite 303, Grand Cayman, Cayman Islands.
- (c) Rhino Cayman's principal business is making investments. Mr. Pelham is the sole shareholder and a director of Rhino Cayman and Mr. Pelham is the Chairman and a shareholder of the Issuer.
- (d) During the past five years, neither (1) Rhino Cayman nor any of its officers or directors, nor (2) Mr. Pelham, have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors).
- (e) During the past five years, neither (1) Rhino Cayman nor any of its officers or directors, nor (2) Mr. Pelham, have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Rhino Cayman is a Cayman Islands exempted company. Mr. Pelham is a British citizen.

Item 3. Source and Amount of Funds or Other Consideration

No Reporting Person has purchased Ordinary Shares in the past sixty (60) days.

Item 4. Purpose of Transaction

The Reporting Persons acquired and hold the securities of the Issuer for investment purposes. Other than as discussed herein, the Reporting Persons do not have any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any other person; (h) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act; or (j) any similar action to those enumerated above. The Reporting Persons may acquire additional securities of the Issuer, or retain, or sell all or a portion of the securities then held in open market or in privately negotiated transactions. Mr. Pelham is the Chairman of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to the matters described in this Item 4. On August 14, 2026, the Issuer entered into an Amended and Restated Sale and Purchase Agreement (the "A&R SPA") with the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries ("Resulticks"). The A&R SPA is attached hereto as Exhibit 99.1. Pursuant to the A&R SPA, the Issuer agreed to acquire all of the issued and outstanding share capital of Resulticks, held by the Sellers, in exchange for US\$1.05 billion, payable entirely in equity through the issuance of 600,000,000 newly issued Ordinary Shares to the Sellers pro rata to their respective ownership of Resulticks based upon the agreed to share price of US\$1.75 per share. It is expected that the Transaction will close on or before October 30, 2026. However, the closing of the Transaction is subject to various conditions and there can be no assurance that the Transaction will close. In connection with the Transaction, and pursuant to the A&R SPA and the Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Mr. Pelham, Rhino Cayman, Radhika Sundaram and Rambachthavachalam Dhakshina Moorthy (the "Deed of Undertaking"), the parties have agreed that Mr. Pelham and Rhino Cayman shall terminate and cancel the 51% Warrant, the Outstanding IPO Warrants, as defined below, and all restricted stock units ("RSUs") and performance stock units ("PSUs"), including the 1,771 RSUs and 1,771 PSUs issued to Mr. Pelham pursuant to the Issuer's Incentive Plan. The Deed of Undertaking is attached hereto as Exhibit 99.2. The "51% Warrant" is the 4,170,520 warrants to purchase 51% of the outstanding Ordinary Shares at time of exercise at a price of \$6.13 per warrant, which was granted by the Issuer to Rhino Cayman on July 15, 2024 and expires on May 27, 2029. The "Outstanding IPO Warrants" are the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029. In exchange for Rhino Cayman's termination and cancellation of the 51% Warrant, Outstanding IPO Warrants, RSUs and PSUs, pursuant to the A&R SPA and the Deed of Undertaking, Rhino Cayman will be allotted and issued 40 million Ordinary Shares at the closing of the Transaction (the "Rhino Shares"). The Rhino Shares are subject to forfeiture in accordance with the terms of the A&R SPA and the Deed of Undertaking.

Item 5. Interest in Securities of the Issuer

- (a) Rhino Cayman beneficially owns (i) 731,707 Ordinary Shares and (ii) 32,316,366 Ordinary Shares underlying warrants, which are exercisable within the next sixty (60) days, which amounts to 33,048,073 Ordinary Shares or 40.1% of the total outstanding Ordinary Shares. Rhino Cayman owns the following warrants. (i) Rhino Cayman the 51% Warrant, which if fully exercised, will result in the issuance of shares equal to 51% of the Issuer's outstanding Ordinary Shares at the time the warrants are exercised and such amount will be prorated in the event of partial

exercise of the warrants (for the purpose of this Schedule 13D we have assumed these warrants are exercisable for 26,566,366 Ordinary Shares which is 51% of the 50,130,130 Ordinary Shares the Issuer had issued outstanding as of August 10, 2026), and (ii) the Outstanding IPO Warrants which consist of the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029.. Mr. Pelham beneficially owns (i) 303,400 Ordinary Shares in his own name and (ii) 33,048,073 Ordinary Shares beneficially held by Rhino Cayman, which amounts to 33,351,473 Ordinary Shares or 40.5% of the total outstanding Ordinary Shares. Mr. Pelham individually and through his position as director of Rhino Cayman, may be deemed to hold the power to vote or direct the vote and dispose of or direct the disposition of the Ordinary Shares beneficially held by the Reporting Persons.

(b) Rhino Cayman beneficially owns (i) 731,707 Ordinary Shares and (ii) 32,316,366 Ordinary Shares underlying warrants, which are exercisable within the next sixty (60) days, which amounts to 33,048,073 Ordinary Shares or 40.1% of the total outstanding Ordinary Shares. Rhino Cayman owns the following warrants. (i) Rhino Cayman the 51% Warrant, which if fully exercised, will result in the issuance of shares equal to 51% of the Issuer's outstanding Ordinary Shares at the time the warrants are exercised and such amount will be prorated in the event of partial exercise of the warrants (for the purpose of this Schedule 13D we have assumed these warrants are exercisable for 26,566,366 Ordinary Shares which is 51% of the 50,130,130 Ordinary Shares the Issuer had issued outstanding as of August 10, 2026), and (ii) the Outstanding IPO Warrants which consist of the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029.. Mr. Pelham beneficially owns (i) 303,400 Ordinary Shares in his own name and (ii) 33,048,073 Ordinary Shares beneficially held by Rhino Cayman, which amounts to 33,351,473 Ordinary Shares or 40.5% of the total outstanding Ordinary Shares. Mr. Pelham individually and through his position as director of Rhino Cayman, may be deemed to hold the power to vote or direct the vote and dispose of or direct the disposition of the Ordinary Shares beneficially held by the Reporting Persons.

(c) On August 17, 2026, Mr. Pelham sold 294,380 Ordinary Shares in a private transaction for \$294,380 or \$1.00 per share. On August 17, 2026, Rhino Cayman sold 6,908,540 Ordinary Shares in three separate private transactions for aggregate consideration of \$6,908,540 or \$1.00 per share.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares owned by the Reporting Persons.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

On November 7, 2025, the Issuer granted Mr. Pelham Restrictive Share Units ("RSUs") to acquire 1,771 Ordinary Shares. The RSUs vest 1/3 on March 31, 2026, 1/3 on March 31, 2027, and 1/3 on March 31, 2028, provided certain conditions are satisfied. On November 7, 2025, the Issuer issued Mr. Pelham Performance Share Units ("PSUs") to acquire 1,771 Ordinary Shares. The PSUs all vest on March 31, 2028, provided certain conditions are satisfied. On August 14, 2026, the Issuer entered into an Amended and Restated Sale and Purchase Agreement (the "A&R SPA") with the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries ("Resulticks"). The A&R SPA is attached hereto as Exhibit 99.1. Pursuant to the A&R SPA, the Issuer agreed to acquire all of the issued and outstanding share capital of Resulticks, held by the Sellers, in exchange for US\$1.05 billion, payable entirely in equity through the issuance of 600,000,000 newly issued Ordinary Shares to the Sellers pro rata to their respective ownership of Resulticks based upon the agreed to share price of US\$1.75 per share. It is expected that the Transaction will close on or before October 30, 2026. However, the closing of the Transaction is subject to various conditions and there can be no assurance that the Transaction will close. In connection with the Transaction, and pursuant to the A&R SPA and the Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Mr. Pelham, Rhino Cayman, Radhika Sundaram and Rambachthavachalam Dhakshina Moorthy (the "Deed of Undertaking"), the parties have agreed that Mr. Pelham and Rhino Cayman shall terminate and cancel the 51% Warrant, as defined below, the Outstanding IPO Warrants, as defined below, and all restricted stock units ("RSUs") and performance stock units ("PSUs"), including the 1,771 RSUs and 1,771 PSUs issued to Mr. Pelham pursuant to the Issuer's Incentive Plan. The Deed of Undertaking is attached hereto as Exhibit 99.2. The "51% Warrant" is the 4,170,520 warrants to purchase 51% of the outstanding Ordinary Shares at time of exercise at a price of \$6.13 per warrant, which was granted by the Issuer to Rhino Cayman on July 15, 2024 and expires on May 27, 2029. The "Outstanding IPO Warrants" are the following warrants granted by the Issuer to Rhino Cayman (i) IPO Warrant No. 1 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025, at a subscription price of USD 8.24 per Ordinary Share, which expire on April 23, 2028, (ii) IPO Warrant No. 2 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 10.24 per Ordinary Share, which expire on July 23, 2028, and (iii) IPO Warrant No. 3 - warrants to purchase 2,250,000 Ordinary Shares granted on January 23, 2025 at a subscription price of USD 12.32 per Ordinary Share, which expire on January 23, 2029. In exchange for Rhino Cayman's termination and cancellation of the 51% Warrant, Outstanding IPO Warrants, RSUs and PSUs, pursuant to the A&R SPA and the Deed of Undertaking, Rhino Cayman will be allotted and issued 40 million

Ordinary Shares at the closing of the Transaction (the "Rhino Shares"). The Rhino Shares are subject to forfeiture in accordance with the terms of the A&R SPA and the Deed of Undertaking. Mr. Pelham is a director and the sole equityholder of Rhino Cayman, which is an investment holding company and Mr. Pelham is the Chairman and a shareholder of Diginex Limited. A Joint Filing Agreement is attached hereto as Exhibit 99.1.

Item 7. Material to be Filed as Exhibits.

Exhibit No. Description 99.1. Amended and Restated Sale and Purchase Agreement, dated August 14, 2026, by and between Diginex Limited and the Sellers, who own 100% of the equity interests in Resulticks Global Companies Pte. Limited and its subsidiaries, is attached as Exhibit 10.1 to the Issuer's Form 6-K filed with the Commission on August 17, 2026, and is incorporated herein by reference. 99.2 Amended and Restated Deed of Undertaking, dated August 14, 2026, by and between Miles Christian Pelham, Rhino Ventures Limited, Radhika Sundaram and Rambachthavachalam Dhakshina Moorthy, is attached as Exhibit 10.2 to the Issuer's Form 6-K filed with the Commission on August 17, 2026, and is incorporated herein by reference. 99.3 Joint Filing Agreement by and among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Rhino Ventures Limited

Signature: /s/ Miles Pelham
Name/Title: Miles Pelham/Director
Date: 08/21/2026

Miles Pelham

Signature: /s/ Miles Pelham
Name/Title: Miles Pelham/Director
Date: 08/21/2026

Joint Filing Agreement

In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of August 21, 2026.

Rhino Ventures Limited,
a Cayman Islands company

By: /s/ Miles Pelham

Name: Miles Pelham

Title: Director

Miles Pelham

/s/ Miles Pelham
